---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-115713"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:50:41.409773+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Avenue Therapeutics completes acquisition of Baergic Bio and its CNS asset BAER-101

## Summary
- Acquired majority of Baergic Bio shares from Fortress Biotech; Baergic now a subsidiary of Avenue.
- Baergic's lead compound BAER-101 is a selective GABA-A α2/3 PAM in-licensed from AstraZeneca with safety data in over 700 patients.
- Closing conditions included $7.5M equity raise and repurchase of InvaGen's shares in Avenue.
- CEO Alexandra MacLean said BAER-101 has potential for orphan and larger CNS indications.

## SEC filing metadata
- accession: 0001104659-22-115713
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465922115713/0001104659-22-115713-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465922115713/tm2229538d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-115713
- JSON: https://secwatch.observer/filing/0001104659-22-115713.json
- Plain text: https://secwatch.observer/filing/0001104659-22-115713.txt

## Key facts
- M&A Transactions
  AVENUE THERAPEUTICS, INC. completed an acquisition involving Fortress Biotech, Inc. (closed 2022-11-08).
  - Action: acquisition
  - Counterparty: Fortress Biotech, Inc.
  - Closing: 2022-11-08
  source text: On November 8, 2022, following the satisfaction of the closing conditions of the Contribution Agreement, the Company completed the acquisition of a majority of the outstanding shares (common and preferred) of Baergic from Fortress.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465922115713/0001104659-22-115713-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.